Gilead Sciences' (NASDAQ: GILD)quarterly updates have almost become boring. The biotech's fourth-quarter resultsannounced in February, for example, were similar to results from last year: HIV sales up, with hepatitis C virus (HCV) sales, total revenue, and earnings down.
Gilead Sciences' First-Quarter Twist: Weak HIV Sales
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться